We use cookies to improve your browsing experience on our website.
Please visit our Privacy Notice for more information about cookies and how we use them. We recommend that you accept the use of cookies for better navigation.

PROMOGRAN PRISMA™ Wound Balancing Matrix

Products described on this website (and associated product information), may not be available for sale in all markets as a result of local regulatory requirements. For information regarding product availability in your market, please contact your local Acelity/KCI representative here.

A Clinically Proven Combination

PROMOGRAN PRISMA™ Matrix is comprised of a sterile, freeze dried composite of 44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC. Silver-ORC contains 25% w/w ionically bound silver, a well-known antimicrobial agent.

Optimum wound environment
PROMOGRAN PRISMA™ Matrix maintains a physiologically moist microenvironment at the wound surface. This environment is conducive to granulation tissue formation, epithelization and optimal wound healing. What is the role of silver in PROMOGRAN PRISMA™ Matrix? The dressing contains ionically bound silver, a well-known broad spectrum antimicrobial agent1
 

To order any of the products listed below, please contact your KCI representative or call your local KCI Office. Click here to contact us.


  • Overview
  • How it Works
  • Indications & Applications
  • Evidence & Outcomes
  • Ordering

Overview

Reduction in Wounds Displaying Signs of  Infection

In a 14-week RCT comparing PROMOGRAN PRISMA Matrix (n=25), with Control (n= 15), the number of patients withdrawn from the study due to infection was significantly greater in the control group 0% VS. 31% (p=0.012)2 (n=40) 

79% VS. 43% For the Standard of care (rate of healing was characterized as >50% reduction in wound size)2

Collagen-14-week-study.png

 


 

What is ORC?

Cellulose is a major component of all plants. Once oxidized, ORC (Oxidized Regenerated Cellulose) is completely bioresorbable, and readily degrades through fluid absorption and subsequent gelling3

What-is-Collagen.png

 

 

 

 

How it Works

  • ABOUT
  • SPECIFICATIONS

Maintains an optimum wound-healing environment

In the presence of exudate, PROMOGRAN PRISMA™ Matrix transforms into a soft, conformable, biodegradable gel, allowing contact with all areas of the wound. 

PROMOGRAN PRISMA™ Matrix maintains a physiologically moist microenvironment at the wound surface. This environment is conducive to granulation tissue formation, epithelialization and optimal wound healing.

  • Optimum wound environment
  • Clinically proven
Product description 
 

PROMOGRAN™ Matrix Wound Dressing is comprised of a sterile, freeze dried composite of 45% oxidized regenerated cellulose (ORC) and 55% collagen.
PROMOGRAN PRISMA™ Matrix is comprised of a sterile, freeze dried composite of 44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC.
Silver-ORC contains 25 % w/w ionically bound silver, a well-known an􀆟microbial agent. PROMOGRAN™ and PROMOGRAN PRISMA™ Matrix modulates and
re-balances the wound environment by the unique combina􀆟on of3:

1. Binding and inac􀆟va􀆟on of proteases (i.e. matrix metallo proteases, elastase and plasmin) which have been shown to be detrimental in excess in chronic wounds.
2. Binding and protec􀆟on of naturally occurring growth factors against degrada􀆟on by these excess proteases.

Indications & Applications

  • INDICATIONS
  • APPLICATIONS
Specific indications, contraindications, warnings, precautions and safety information exist for KCI products and therapies. Healthcare providers should review the product User Manual, Safety Information and/or Instructions for Use prior to application.

PROMOGRAN PRISMA™ Matrix is indicated for the management of wounds healing by secondary intent which are clear of necrotic tissue including:
  • Diabetic ulcers
  • Venous ulcers
  • Pressure ulcers
  • Ulcers caused by mixed vascular aetiologies
  • Traumatic and surgical wounds

Can be used under compression therapy.

PROMOGRAN PRISMA™ Matrix is a primary dressing that can be cut to fit the wound with scissors and must be covered with either gauze, a non-adhering or a hydropolymer dressing in order to maintain a moist wound healing environment.

 

Applications

 

Storage

PROMOGRAN PRISMA™ Matrix should be stored away from direct light. Over-exposure to light may cause some discolouration, however this does not affect the release of silver from the dressing. Before treatment, dry necrotic tissue must be first removed by surgical, enzymatic or autolytic debridement

 

  • For optimal effect, apply PROMOGRAN PRISMA™ Matrix directly to the whole wound bed.
  • For a wound with low or no exudate apply PROMOGRAN PRISMA™ Matrix and hydrate with saline or Ringer's solution. This will initiate the gel forming process.
  • After hydration the PROMOGRAN PRISMA™ Matrix gel will intimately contact the wound
  • The biodegradable gel is naturally absorbed over time.
 
PROMOGRAN PRISMA™ Matrix must be covered with either gauze, a non-adhering or a hydropolymer dressing in order to maintain a moist wound healing environment.
 
After initial application, re-treat the wound with PROMOGRAN PRISMA™ Matrix up to every 72 hours depending upon the amount of exudate. It is not necessary to remove any residual PROMOGRAN PRISMA™ Matrix. For heavily exuding or infected wounds it may be necessary to retreat the wound with PROMOGRAN PRISMA™ Matrix every 24 hours.
 

Evidence & Outcomes


The efficacy of PROMOGRAN PRISMA™ Matrix is supported by clinical evidence, including a published RCT. Acelity Clinical Evidence is a resource for healthcare professionals to explore preclinical, clinical, and review articles discussing the use of Acelity™ products. 

 

Clinical Evidence

Additional summary of evidence and outcomes.
TITLE A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Veves A, et al.
TITLE Wound conditioning of a deep tissue defect including exposed bone after tumour excision using PROMOGRAN* Matrix, a protease-modulating matrix.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2005
AUTHORS Tausche AK, et al.
TITLE The role of oxidized regenerated cellulose / collagen in wound repair: effects in vitro on fibroblast biology and in vivo in a model of compromised healing
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Hart, et al.
TITLE Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Kakagia DD, et al. 
TITLE Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Kakagia DD, et al. 
TITLE Effect of oxidized regenerated cellulose/collagen matrix on proteases in wound exudate of patients with diabetic foot ulcers
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Ulrich, et al.
TITLE Modulation of the chronic wound environment; an in vitro evaluation of advanced wound therapies
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Cullen B, et al.
TITLE Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2013
AUTHORS Gottrup F, et al.
TITLE Prospective and randomised evaluation of the protease-modulating effect of oxidised regenerated cellulose /collagen matrix treatment in pressure sore ulcers
View Abstract on PubMed
STUDY TYPE All levels
DATE 2015
AUTHORS Smeets, et al.
TITLE Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2006
AUTHORS Lobmann R, et al.
TITLE Expression of Matric-Metalloproteases in the Fluid of Chronic Diabetic Foot Wounds Treated with a Protease Absorbent Dressing
View Abstract on PubMed
STUDY TYPE All levels
DATE 2011
AUTHORS Motzkau M, et al.
TITLE The healing properties of Promogran in venous leg ulcers.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Vin F, et al.
TITLE The benefits of oxidized regenerated cellulose (ORC) for wound healing
View Abstract on PubMed
STUDY TYPE All levels
DATE 2010
AUTHORS Cullen B, et al.
TITLE Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Ghatnekar O, et al.
TITLE Randomized comparative trial of a collagen/oxidized regenerated cellulose dressing in the treatment of neuropathic diabetic foot ulcers
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Lazaro-Martinez, et al.
TITLE Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration
View Abstract on PubMed
STUDY TYPE All levels
DATE 2008
AUTHORS Smeets, et al.
TITLE Collagen ORC rebalances the wound environment
View Abstract on PubMed
STUDY TYPE All levels
DATE 2003
AUTHORS Cullen B, et al.
TITLE Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Cullen B, et al.
TITLE Prospective and randomised evaluation of the protease-modulating effect of oxidised regenerated cellulose/collagen matrix treatment in pressure sore ulcers
View Abstract on PubMed
STUDY TYPE All levels
DATE 2015
AUTHORS Kloeters O, et al. 
TITLE Some effects of a topical collagen-based matrix on the microcirculation and wound healing in patients with chronic venous leg ulcers: preliminary observations
View Abstract on PubMed
STUDY TYPE All levels
DATE 2005
AUTHORS Wollina U, et al.

To order any of the products listed below, please contact your KCI representative or call your local KCI Office. Click here to contact us.

  • PROMOGRAN PRISMA™ Matrix

    PRODUCT PRODUCT CODE   ordering option
     
    FS-380x380-promogran-prisma-packs.jpg

    PROMOGRAN PRISMA™ Matrix

    28cm2

     
    NHS Supply Chain Code
    ELZ 086

    Drug Tariff Code
    320-8105
    10
     
    FS-380x380-actisorb-silver-front.jpg

    PROMOGRAN PRISMA™ Matrix

    123cm2


    NHS Supply Chain Code
    ELZ 087

    Drug Tariff Code
    320-8121
    10